Crowdsourced AI Learns To Target Lung Tumors For Radiat...
(Reuters Health) Apr 18, 2019 - In many parts of the world there are not enough radiation oncologists to design and deliver radiation treatments for lung cancer p...
Many Young Cancer Patients Regret Initial Treatment Dec...
(Reuters Health) Apr 18, 2019 - Most teens and young adults with cancer want a voice in how their tumors are treated, but almost one in four express regret about ...
May 14, 2019: Meeting of the Oncologic Drugs Advisory C...
(FDA.gov) Apr 10, 2019 - During the morning session, the committee will discuss new drug application (NDA) 211810 for pexidartinib capsule, submitted by Daiichi S...
Featured Content
Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Rana McKay, Assistant Professor of Medicine, University of California San Diego, discuss renal cell carcinoma (RCC) clinical highlights from ASCO GU 2019
We highlight pivotal AACR trial data with a focus on immunotherapies in hard-to-treat cancers, such as pancreatic cancer and mesothelin-expressing solid tumors.
Chemotherapy-induced nausea and vomiting (CINV) is a common and costly driver of care. Certain actions are available to drive down costs. Explore them here.
In an exclusive to OBR, onPoint presents their Commercial Plan Report Card that compares commercial payers in terms of denial rates and in days to pay. Results are found herein.
Podcasts
Renal Cell Carcinoma (RCC) – Rana McKay, MD, and Robert Figlin, MD, discuss clinical highlights from ASCO GU 2019
Expert Video Insights
Todd Schonherz on the formation of the American Oncology Network (AON)
Alexander Spira, MD, PhD, FACP, on how Virginia Cancer Specialists is embracing value-based care
OBR Green
April 2019 Edition
We highlight pivotal AACR trial data with a focus on immunotherapies in hard-to-treat cancers, such as pancreatic cancer and mesothelin-expressing solid tumors.
April 2019 Edition
Chemotherapy-induced nausea and vomiting (CINV) is a common and costly driver of care. Certain actions are available to drive down costs. Explore them here.
April 2019 Edition
In an exclusive to OBR, onPoint presents their Commercial Plan Report Card that compares commercial payers in terms of denial rates and in days to pay. Results are found herein.
BlogHHS Takes Aim at Rebates, But Will Lower Drug Costs Fol...
Feb 27, 2019
As part of its attempt to lower drug costs and increase transparency, the US Department of Health and Human Services (HHS) announced a proposed rule on January 31...
ASCO Genitourinary Cancers Symposium 2019 Preview
Feb 11, 2019
As the Genitourinary Cancers (GU) Symposium gets under way in San Francisco February 13-16 2019, at a pre-meeting Presscast, ASCO experts singled out three abstra...
Guidelines Ignored in Supportive and Palliative Care
Dec 12, 2018
SAN DIEGO—Too often, strategies known to be effective within the realm of supportive and palliative cancer care remain on the back burner. This often-observed f...
OBR Tools
Stemming from the user preference that you set, stay informed and increase your productivity via 27/7 web based access to Ontellitrac and a customized email alert system summarizing the most recent oncology-specific information available.
Learn More
The Oncology Business Dynamics Learning Platform addresses the need to have a high level of understanding of the non-clinical issues that are influencing the decision making process for hem/oncs today.
Learn MoreOriginal articles, thought leader interviews, and other resources covering testing, patient selection and treatment options in AML
Supported by:
We explore the scope of the escalating cost of cancer care, discuss the factors that contribute to the total cost of cancer care, and provide resources to help us all understand the facts regarding the cost of cancer care.
Sponsored by:
[by phone or online via webcast]
[by phone or online via webcast]
[by phone or online via webcast]
Berlin, Germany
Shenzhen, China
Denver, CO
San Diego, CA
Atlanta, GA
Denver, CO
[by phone or online via webcast]
[by phone or online via webcast]
Chicago, IL
Portland, OR
RAI Amsterdam, The Netherlands
Zeist, Netherlands
Lugano, Switzerland
Bellevue, WA
Austin, TX
Baltimore, MD
San Diego, CA
San Diego, CA
Brussels, Belgium
Chicago, IL
San Francisco, CA
Barcelona, Spain
Buenos Aires, Argentina
San Francisco, CA
Orlando, FL
San Antonio, TX
New Orleans, LA
San Francisco, CA
San Francisco, CA
Scottsdale, AZ
Washington, D.C.
San Diego, CA
Chicago, IL
Top 5 Upcoming Events
| Date | Company and Product |
|---|---|
| Apr 11 | Merck , |
| May 24 | Incyte Corp., |
| Jun 10 | Merck , |
| Jun 17 | Merck & Co., |
| Jun 20 | Merck, |
FDA Approves Expanded Monotherapy Label for Merck’s KEYTRUDA&...
"This new approval is more likely to lead to worse care rather tha..."
PBM Middlemen Continue to Dodge Responsibility for Patient Sufferin...
"PBMs are getting more brazen in how they delay and deny cancer pa..."
ASCO Announces New Task Force To Address Rural Cancer Care Gap
"When the Medicare fee schedule pays the same for clinic-based as ..."
Apr 19
https://t.co/HiyFI7X0DE May 14, 2019: Meeting of the Oncologic Drugs Advisory Committee Meeting...
Apr 19
(Reuters Health) Apr 18, 2019 - In many parts of the world there are not enough radiation oncologists to design and deliver radiation...
Apr 18
https://t.co/OcdEF76xie Bispecific Antibodies: FDA...
Apr 18
https://t.co/NozsmBzeTq Triple Negative...
Apr 18
https://t.co/822c33cbFF Cervical Cancer Subtype Rising in Some Sub-Populations
Apr 18
https://t.co/PNmjX8umc6 ASCO Announces...
Apr 17
https://t.co/4f2d2u7hE5 Agilent Receives an Expanded FDA Approval for its Companion...
Apr 17
https://t.co/nelgJWlEpA U Penn Begins Human...
Apr 17
https://t.co/EyzVQT3Q1f...
Apr 16
https://t.co/9Oqrff30Ur Don’t Count on 23andMe to Detect Most Breast Cancer...
Today's Oncology News
Role of Molecular Testing in AML
Total Cost of Cancer Care
0.16
-0.09